Does Mounjaro affect liver enzymes — and should you be concerned?

Do liver enzymes actually go up on Mounjaro, and how often?

In the SURMOUNT-1 trial, which enrolled thousands of adults with obesity over 72 weeks, small increases in alanine aminotransferase (ALT) were observed more often in the tirzepatide groups than in the placebo group. These elevations were mostly mild (within two to three times the upper limit of normal) and the majority did not progress or require any change to treatment. Clinically significant liver enzyme rises were uncommon. The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, does not list liver injury as a known risk, but it does note that hepatobiliary effects warrant attention if symptoms develop.

There is an important distinction worth making. Many people starting Mounjaro already have elevated ALT before their first pen, because excess liver fat (a feature of metabolic-associated fatty liver disease) is itself one of the most common drivers of high enzyme readings in people with obesity. That means the number on a blood test result does not always mean treatment is causing harm; sometimes the opposite is happening.

A useful checking habit: if you have recent blood results from your GP, look at the ALT figure noted before you started treatment. Comparing pre- and post-treatment values gives a clinician a meaningful baseline, something worth flagging at your next review rather than waiting until your annual check.

Can Mounjaro actually help a fatty liver?

This is where the evidence becomes genuinely interesting. Tirzepatide's dual GIP and GLP-1 receptor mechanism reduces appetite and slows gastric emptying, but it also appears to drive meaningful reductions in hepatic fat. Several sub-studies of the SURMOUNT programme observed significant decreases in liver fat fraction measured by MRI in participants with metabolic-associated steatohepatitis. The NHS medicines page for tirzepatide notes that, as with other GLP-1-based medicines, favourable effects on liver fat have been observed, though tirzepatide does not currently hold a specific UK licence for liver disease. You can read more about the liver-specific data on tirzepatide and liver enzymes and on our page covering how Mounjaro relates to liver health more broadly.

For context, semaglutide (Wegovy) received conditional MHRA approval in July 2026 for a form of fatty liver disease (MASH) which underlines how actively this class of medicine is being studied in liver-related conditions. Tirzepatide trials in MASH are ongoing. The science is moving quickly; what is known today may widen considerably within a year or two.

What if you already have elevated liver enzymes or a liver condition?

Having raised enzymes before starting Mounjaro does not automatically rule it out, but it does change the conversation. A prescriber will want to understand the cause. Enzymes raised by simple fatty liver disease (where treatment may plausibly help) sit in a very different clinical place from enzymes raised by cirrhosis, active hepatitis, or alcohol-related liver disease. For anyone with significant liver disease, a specialist opinion before or alongside starting treatment is the sensible route. The broader question of Mounjaro and liver health covers these distinctions in more detail.

Alcohol is also worth raising here. Tirzepatide slows gastric emptying, which changes how quickly alcohol enters the bloodstream and affects the liver. If you drink regularly, the interaction between that and any background enzyme elevation is something to discuss openly with your prescriber. Our page on alcohol and Mounjaro sets out what is known.

The NHS tirzepatide medicines page and the Mounjaro SmPC on the eMC are the authoritative references for the full contraindication and caution list. Neither replaces a clinical assessment of your specific situation.

Who should you speak to, and when is it urgent?

For most people on Mounjaro with no known liver condition, liver enzyme monitoring is not routinely required, though some prescribers will check bloods at baseline, particularly if there is a history of fatty liver or abnormal results. If your GP has flagged elevated enzymes in the past, mention it during your consultation before treatment starts, and if you are planning a pregnancy or think you may be pregnant, our page on whether Mounjaro affects pregnancy is also worth reading before you begin.

Seek prompt medical attention if you develop any of the following during treatment: persistent pain in the upper right abdomen, yellowing of the skin or whites of the eyes (jaundice), very dark urine, or unusual fatigue alongside abdominal discomfort. These are potential signs of a biliary or hepatic problem that need assessment the same day, not a wait-and-see. Mounjaro does increase bile secretion, and gallbladder problems (including gallstones) are a known side effect in a small proportion of users, which can produce a similar pattern of symptoms and elevated liver enzymes.

Symptoms that feel worrying should never be self-managed by adjusting your dose. Your prescriber, GP, or in an urgent situation a pharmacist or 111, is the right first call. If you have questions about starting treatment and your liver history, a free consultation with our clinical team is the place to start, your answers are read the same day by a real prescriber, not processed by an algorithm. You can also read more about the Mounjaro treatment overview or explore weight-loss treatment options more broadly.